Deferasirox
Top View
- Iron Chelating Agents (Desferal Exjade Ferriprox Jadenu) C15214-A
- WHO Drug Information Vol
- Lists of Medicinal Products for Rare Diseases in Europe*
- Exjade (Deferasirox) Tablets Label
- An Open-Label, Phase II, Randomized, Pilot Study to Assess the Effect In
- Neonatal Murine Engineered Cardiac Tissue Toxicology Model Impact Of
- Wo 2010/099542 A2
- Chelation Therapy Hs-092
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Exjade, INN-Deferasirox
- Is Ferroptosis Involved in ROS-Induced Testicular Lesions in a Varicocele Rat Model? Erfaneh Shaygannia1, Mohammad H
- Formulation Development and Evaluation of Deferasirox Dispersible Tablets
- Use of Chelating Agents in Medicine
- Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
- Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-Based Case Report
- The Cardioprotective Effect of Dexrazoxane (Cardioxane) Is Consistent with Sequestration of Poly(ADP-Ribose) by Self-Assembly and Not Depletion of Topoisomerase 2B
- Iron Chelators
- 5.01.613 Oral Iron Chelating Agents